Patents by Inventor Mike E. Lizarzaburu

Mike E. Lizarzaburu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20240092731
    Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
    Type: Application
    Filed: July 14, 2023
    Publication date: March 21, 2024
    Inventors: Yiumo CHAN, Emil D. KAKKIS, Alexandra TROTIER-FAURION, William F. BRUBAKER, Arjun NATESAN, Paul LEE, Sharyl FYFFE-MARICICH, David LAPOINTE, Mike E. LIZARZABURU
  • Creatine prodrugs, compositions and methods of use thereof
    Patent number: 11753369
    Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: September 12, 2023
    Assignee: Ultragenyx Pharmaceutical Inc.
    Inventors: Yiumo Chan, Emil D. Kakkis, Alexandra Trotier-Faurion, William F. Brubaker, Arjun Natesan, Paul Lee, Sharyl Fyffe-Maricich, David Lapointe, Mike E. Lizarzaburu
  • CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220227703
    Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
    Type: Application
    Filed: March 28, 2022
    Publication date: July 21, 2022
    Inventors: Yiumo CHAN, Emil D. KAKKIS, Alexandra TROTIER-FAURION, William F. BRUBAKER, Arjun NATESAN, Paul LEE, Sharyl FYFFE-MARICICH, David LAPOINTE, Mike E. LIZARZABURU
  • Creatine prodrugs, compositions and methods of use thereof
    Patent number: 11332438
    Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: May 17, 2022
    Assignee: Ultragenyx Pharmaceutical Inc.
    Inventors: Yiumo Chan, Emil D. Kakkis, Alexandra Trotier-Faurion, William F. Brubaker, Arjun Natesan, Paul Lee, Sharyl Fyffe-Maricich, David Lapointe, Mike E. Lizarzaburu
  • CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210002211
    Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
    Type: Application
    Filed: December 3, 2018
    Publication date: January 7, 2021
    Inventors: Yiumo CHAN, Emil D. KAKKIS, Alexandra TROTIER-FAURION, William F. BRUBAKER, Arjun NATESAN, Paul LEE, Sharyl FYFFE-MARICICH, David LAPOINTE, Mike E. LIZARZABURU
  • Substituted benzofused heterocycles
    Patent number: 7572783
    Abstract: The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: August 11, 2009
    Assignee: Amgen Inc.
    Inventors: Xi Chen, Xiaoqi Chen, Richard Victor Connors, Kang Dai, Ying Fu, Juan C. Jaen, Yong-Jae Kim, Leping Li, Mike E. Lizarzaburu, Jeffrey T. Mihalic, Stephen J. Shuttleworth
  • Polyamine-mediated transfection
    Publication number: 20040077888
    Abstract: The present invention provides cationic lipids and methods that facilitate nucleic acid delivery and which also yield biologically benign metabolites following transfection. The compounds are lipidic polyamines that use a pentaerythritol scaffold to link different hydrophobic and DNA-binding domains.
    Type: Application
    Filed: May 30, 2003
    Publication date: April 22, 2004
    Applicants: The Regents of the University of California, Genteric, Inc.
    Inventors: Edmund J. Niedzinski, Michael H. Nantz, Michael Bennett, Mike E. Lizarzaburu